| cardiovascular prevention | versus placebo or control No demonstrated result for efficacy clofibrate inferior to placebo in terms of all cause deaths in WHO clofibrate, 1978 clofibrate inferior to placebo in terms of non cardiovascular death in WHO clofibrate, 1978 clofibrate inferior to placebo in terms of non cardiovascular death in CDP Clofibrate, 1975 clofibrate inferior to placebo in terms of venous thromboembolism in CDP Clofibrate, 1975 | 11 trials | meta-analysis | | | Trial | control | p<0.05 | harm | NS |
|---|
| SCOR, 1990 | colestipol+clofibrate vs placebo | | | all cause deaths 0.00 [0.00; NaN] coronary deaths NaN [NaN; NaN] non cardiovascular death 0.00 [0.00; NaN] | | WHO clofibrate, 1978 | clofibrate vs placebo | MI non fatal 0.75 [0.60; 0.94] | all cause deaths 1.27 [1.01; 1.59] non cardiovascular death 1.41 [1.07; 1.85] | Pancreatitis ∞ [NaN; ∞] coronary deaths 1.12 [0.76; 1.65] coronary events 0.83 [0.68; 1.00] décès par cancer 1.35 [0.96; 1.91] cardiac death 1.12 [0.76; 1.65] | | CDP Clofibrate, 1975 | clofibrate vs placebo | coronary deaths 0.85 [0.73; 0.98] cardiac death 0.85 [0.73; 0.98] | non cardiovascular death 1.55 [1.20; 2.01] venous thromboembolism 1.78 [1.08; 2.92] | Pancreatitis 0.00 [0.00; NaN] all cause deaths 0.98 [0.87; 1.11] coronary events 0.93 [0.83; 1.04] décès par cancer 1.05 [0.51; 2.20] MI non fatal 0.94 [0.79; 1.13] | | Scottish, 1971 | clofibrate vs placebo | | | all cause deaths 0.98 [0.66; 1.45] coronary deaths 1.02 [0.65; 1.60] coronary events 0.81 [0.60; 1.11] MI non fatal 0.64 [0.38; 1.07] cardiac death 1.02 [0.65; 1.60] non cardiovascular death 0.84 [0.33; 2.10] | | Newcastle, 1971 | clofibrate vs placebo | all cause deaths 0.63 [0.42; 0.95] coronary deaths 0.59 [0.37; 0.93] coronary events 0.63 [0.48; 0.84] cardiac death 0.59 [0.37; 0.93] | | MI non fatal 0.68 [0.44; 1.03] non cardiovascular death 0.89 [0.30; 2.61] | | Harrold, 1969 | clofibrate vs placebo | | | | | Begg, 1971 | clofibrate vs placebo | | | all cause deaths 0.42 [0.14; 1.27] coronary deaths 0.46 [0.15; 1.44] cardiac death NaN [NaN; NaN] | | Acheson, 1972 | clofibrate vs placebo | | | | | VA Neurology Section, 1974 | clofibrate vs placebo | | | | | Cullen, 1974 | clofibrate vs placebo | | | | | Hanefeld, 1991 | clofibrate vs placebo | | | coronary events 1.04 [0.65; 1.67] |
| Trial | Treatments | Patients | Method |
|---|
| SCOR, 1990 | colestipol (15 to 30mg/d) + clofibrate (2g/d) (n=48) vs. diet (n=49) | patients with primary hypercholesterolemia | Parallel groups Sample size: 48/49 Primary endpoint: FU duration: 2.0 years | | WHO clofibrate, 1978 | clofibrate 1.6 g daily (n=5331) vs. olive oil (n=5296)
| primary prevention, Hommes, de 30 à 59 ans
| double blind Parallel groups Sample size: 5331/5296 Primary endpoint: IDM et/ou mort subite et/ou ischémie FU duration: 5.3 years
| | CDP Clofibrate, 1975 | clofibrate 1.8 mg/d (n=1103) vs. placebo (n=2789) | men, 30-64 y | double blind Parallel groups Sample size: 1103/2789 Primary endpoint: Mortalité totale FU duration: 6.2 years | | Scottish, 1971 | clofibrate 1.6-2 g daily (n=350) vs. placebo (n=367) | Hommes et femmes, de 40 à 69 ans | double blind Parallel groups Sample size: 350/367 Primary endpoint: Mort subite, IDM fatal FU duration: 3.4 years | | Newcastle, 1971 | clofibrate 1.5-2 g daily (n=244) vs. placebo (n=253)
| Hommes et femmes < 65 ans
| double blind Parallel groups Sample size: 244/253 Primary endpoint: Décès coronariens et idm non fatal FU duration: 3.6 y
| | Harrold, 1969 | clofibrate (n=30) vs. placebo (n=33)
| diabetic retinopathy
| double-blind Parallel groups Sample size: 30/33 Primary endpoint: FU duration: 1 years
| | Begg, 1971 | clofibrate (n=76) vs. placebo (n=79)
| peripheral arteriopathy
| Parallel groups Sample size: 76/79 Primary endpoint: FU duration: 3.5 y
| | Acheson, 1972 | clofibrate (n=-9) vs. placebo (n=-9)
| cerebral vascular disease
| NA Parallel groups Sample size: -9/-9 Primary endpoint: FU duration: 6 years
| | VA Neurology Section, 1974 | clofibrate (n=268) vs. placebo (n=264)
| treatment of cerebrovascular disease
| Parallel groups Sample size: 268/264 Primary endpoint: FU duration: 1.8 years
| | Cullen, 1974 | clofibrate (n=20) vs. placebo (n=20)
|
| Parallel groups Sample size: 20/20 Primary endpoint: FU duration: 2 years
| | Hanefeld, 1991 | clofibric acid 1.6 g/day (n=379) vs. placebo (n=382) | newly diagnosed middle-aged (30- to 55-yr-old) patients with non-insulin-dependent diabetes mellitus | double-blind Parallel groups Sample size: 379/382 Primary endpoint: NA FU duration: 5 years |
|
